Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654587 · ClinicalTrials.gov registry record · Phase 3
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
A Phase 3 study, sponsored by OSE Immunotherapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT02654587: Clinical Trial Phase 3 study, sponsored by OSE Immunotherapeutics.
NCT02654587 is a Phase 3 study that was terminated before completion, run by OSE Immunotherapeutics. The registered enrollment target is 219 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02654587, a Phase 3 study, was terminated before completion, sponsored by OSE Immunotherapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune checkpoint inhibitor given in first or second-line treatment. The main questions were to compare the survival, the tolerance to treatment and the quality of life of patients between the two arms of treatment (OSE2101 versus standard chemotherapy)
Primary Outcome
OS defined as the time from randomisation to death from any cause in patients with ICI secondary resistance
Interventions
- DRUG Docetaxel
- DRUG Pemetrexed
- BIOLOGICAL OSE2101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 3 |
Why NCT02654587 stopped before completion
NCT02654587 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT02654587 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02654587 about?
NCT02654587 is a clinical study titled "OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure". The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune ...
What is the current status of trial NCT02654587?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2016-02-12. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT02654587?
The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), OSE2101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02654587?
This trial is sponsored by OSE Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02654587's enrollment target sits among peer trials
219 1329th of 2000 higher than 670 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05196035 · 219 participants · Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- NCT05608434 · 219 participants · Phase 1
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
- NCT05773144 · 219 participants · NA
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- NCT05907980 · 219 participants · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI